Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
June 25 2024 - 8:30AM
Business Wire
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial
intelligence and precision medicine, today announced a new
collaboration with United Therapeutics (UT), a leading
biotechnology company focused on providing a brighter future for
patients through the development of novel pharmaceuticals and
technologies. As part of this collaboration, Tempus will develop
and investigate AI-based medical device software to detect patients
at risk of having undiagnosed pulmonary hypertension (PH).
PH is a fatal, progressive disease of the heart and lungs that
affects approximately 1% of the population.1 Despite an increasing
number of available treatments for the disease, the detection or
clinical diagnosis of PH is typically delayed for 2 or more years.2
To help solve this critical problem, Tempus built an algorithm that
automatically analyzes the results of a 12-lead electrocardiogram
(ECG) to identify patients at risk of undiagnosed PH to be further
evaluated by clinicians. The initial findings from this work were
recently presented at the American Thoracic Society International
Conference in San Diego, California on May 22, 2024.
Tempus’ research and development program will leverage Tempus
Next, the company’s AI-enabled care pathway intelligence solution,
to facilitate the deployment of the algorithm at participating
centers. Clinicians will evaluate its ability to detect patients at
risk of undiagnosed PH, and to track clinical outcomes of patients
who are identified for further evaluation, within a prospective
clinical study at up to 60 centers. Tempus and UT plan to
collaborate on this study to investigate the clinical impact of
this technology and gain new insights into the detection and
diagnosis of PH. Tempus expects to engage with the Food and Drug
Administration (FDA) to align on regulatory requirements and FDA
expectations regarding validation of this novel AI-based
algorithm.
“We aim to set a new standard for identifying patients with
pulmonary hypertension by getting novel technology into the hands
of clinicians to enable earlier diagnosis and more effective
disease management,” said Brandon Fornwalt, MD, PhD, Senior Vice
President of Cardiology at Tempus. “Exploring this in a prospective
multicenter study brings us one step closer to realizing the dream
of data-driven precision medicine.”
About Tempus Tempus is a technology company advancing
precision medicine through the practical application of artificial
intelligence in healthcare. With one of the world’s largest
libraries of multimodal data, and an operating system to make that
data accessible and useful, Tempus provides AI-enabled precision
medicine solutions to physicians to deliver personalized patient
care and in parallel facilitates discovery, development and
delivery of optimal therapeutics. The goal is for each patient to
benefit from the treatment of others who came before by providing
physicians with tools that learn as the company gathers more data.
For more information, visit tempus.com.
_____________________________________
1,2
European Heart Journal, Volume 43, Issue
38, 7 October 2022, Pages 3618–3731,
https://doi.org/10.1093/eurheartj/ehac237
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended (the “Securities Act”), and
Section 21E of the Securities Exchange Act of 1934, as amended,
about Tempus and Tempus’ industry that involve substantial risks
and uncertainties. All statements other than statements of
historical facts contained in this press release, including
statements regarding the expected outcomes and benefits of the
collaboration with UT to study use of artificial intelligence to
detect patients at risk for PH, are forward-looking statements. In
some cases, you can identify forward-looking statements because
they contain words such as “anticipate,” “believe,” “contemplate,”
“continue,” “could,” “estimate,” “expect,” “going to,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “will,” or “would” or the negative of these words or
other similar terms or expressions. Tempus cautions you that the
foregoing may not include all of the forward-looking statements
made in this press release.
You should not rely on forward-looking statements as predictions
of future events. Tempus has based the forward-looking statements
contained in this press release primarily on its current
expectations and projections about future events and trends that it
believes may affect Tempus’ business, financial condition, results
of operations and prospects. These forward-looking statements are
subject to risks and uncertainties related to: Tempus’ financial
performance; the ability to attract and retain customers and
partners; managing Tempus’ growth and future expenses; competition
and new market entrants; compliance with new laws, regulations and
executive actions, including any evolving regulations in the
artificial intelligence space; the ability to maintain, protect and
enhance Tempus’ intellectual property; the ability to attract and
retain qualified team members and key personnel; the ability to
repay or refinance outstanding debt, or to access additional
financing; future acquisitions, divestitures or investments; the
potential adverse impact of climate change, natural disasters,
health epidemics, macroeconomic conditions, and war or other armed
conflict, as well as risks, uncertainties, and other factors
described in the section titled “Risk Factors” in Tempus’ Final
Prospectus filed with the Securities and Exchange Commission
(“SEC”) on June 17, 2024, pursuant to Rule 424(b)(4) under the
Securities Act, as well as in other filings Tempus may make with
the SEC in the future. In addition, any forward-looking statements
contained in this press release are based on assumptions that
Tempus believes to be reasonable as of this date. Tempus undertakes
no obligation to update any forward-looking statements to reflect
events or circumstances after the date of this press release or to
reflect new information or the occurrence of unanticipated events,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625657815/en/
Tempus Communications Erin Carron media@tempus.com